Author

J. Merisaari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. Westermarck· 5 shared M. Ohlmeyer· 3 shared A. Kaur· 2 shared C. von Schantz-Fant· 2 shared K. Wennerberg· 2 shared L. Yetukuri· 2 shared M. Jumppanen· 2 shared M. Taipale· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

J. Westermarck

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis

M. Momeny, M. Tienhaara, D. Chakroborty, M. Sharma, R. Varjus, J. Merisaari, A. Padzik, A. Vogt, I. Paatero, K. Kurppa, K. Elenius, T. D. Laajala, J. Westermarck

This study identifies DUSP6 as a driver of HER2 inhibitor tolerance through the Neuregulin/HER3 axis by analyzing the transcriptional changes during the DTP-DTEP transition in HER2+ breast cancer cells.

bioRxiv · Jun 14, 2023 · PreprintCancer Biology

Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell models

O. Denisova, J. Merisaari, R. Huhtaniemi, X. Qiao, A. Kaur, L. Yetukuri, M. Jumppanen, M. Paakkonen, C. von Schantz-Fant, M. Ohlmeyer, K. Wennerberg, O. Kauko, R. Koch, T. Aittokallio, M. Taipale, J. Westermarck

This study identifies a triplet therapy combining AKT, PDK1-4 inhibition, and PP2A reactivation that effectively eradicates brain tumor models by overcoming kinase inhibitor tolerance through combinatorial effects on signaling rewiring, OXPHOS, and apoptosis.

bioRxiv · May 31, 2022 · PreprintCancer Biology

Development of Actionable Targets of Multi-kinase Inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells

O. Denisova, J. Merisaari, A. Kaur, L. Yetukuri, M. Jumppanen, C. von Schantz-Fant, M. Ohlmeyer, K. Wennerberg, T. Aittokallio, M. Taipale, J. Westermarck

The paper develops a platform to identify kinase targets of multi-kinase inhibitors in glioblastoma cells and finds AKT, PDK1, and PDK4 as targets of staurosporine derivatives that synergize with PP2A reactivation.

bioRxiv · Jan 20, 2022Cancer Biology

Circumventing drug treatment? Polyethylenimine functionalized nanoparticles inherently and selectively kill patient-derived glioblastoma stem cells

N. Prabhakar, J. Merisaari, V. Le Joncour, M. Peurla, D. Sen Karaman, E. Casals, P. Laakkonen, J. Westermarck, J. Rosenholm

This study shows that PEI-functionalized nanoparticles selectively kill glioblastoma stem cells by lysosomal membrane rupture without affecting other cancer cells.

bioRxiv · Dec 14, 2020 · PreprintCancer Biology

Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastoma

J. Merisaari, O. V. Denisova, M. Doroszko, V. Le Joncour, P. Johansson, W. P. J. Leenders, D. B. Kastrinsky, Z. Nilesh, G. Narla, P. Laakkonen, S. Nelander, M. Ohlmeyer, J. Westermarck

This study shows that BBB-permeable PP2A activators reduce GB tumor growth and improve survival in mice with diverse GB subtypes.

bioRxiv · Sep 27, 2019 · PreprintCancer Biology